Bon Natural Life (BON) Competitors $1.31 +0.03 (+2.34%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$1.31 0.00 (0.00%) As of 08/8/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsTrendsBuy This Stock BON vs. TRVN, PBLA, HEPA, BPTSY, VIRX, NCNA, MYMD, SYRS, CAPS, and VINCShould you be buying Bon Natural Life stock or one of its competitors? The main competitors of Bon Natural Life include Trevena (TRVN), Panbela Therapeutics (PBLA), Hepion Pharmaceuticals (HEPA), Biophytis (BPTSY), Viracta Therapeutics (VIRX), NuCana (NCNA), MyMD Pharmaceuticals (MYMD), Syros Pharmaceuticals (SYRS), Capstone Therapeutics (CAPS), and Vincerx Pharma (VINC). These companies are all part of the "pharmaceutical products" industry. Bon Natural Life vs. Its Competitors Trevena Panbela Therapeutics Hepion Pharmaceuticals Biophytis Viracta Therapeutics NuCana MyMD Pharmaceuticals Syros Pharmaceuticals Capstone Therapeutics Vincerx Pharma Trevena (NASDAQ:TRVN) and Bon Natural Life (NYSE:BON) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends. Do institutionals & insiders believe in TRVN or BON? 13.6% of Trevena shares are owned by institutional investors. Comparatively, 0.6% of Bon Natural Life shares are owned by institutional investors. 2.7% of Trevena shares are owned by insiders. Comparatively, 26.5% of Bon Natural Life shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is TRVN or BON more profitable? Company Net Margins Return on Equity Return on Assets TrevenaN/A N/A -119.55% Bon Natural Life N/A N/A N/A Do analysts rate TRVN or BON? Trevena presently has a consensus target price of $5.00, indicating a potential upside of 1,900.00%. Given Trevena's stronger consensus rating and higher probable upside, analysts clearly believe Trevena is more favorable than Bon Natural Life.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Trevena 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Bon Natural Life 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has stronger valuation and earnings, TRVN or BON? Bon Natural Life has higher revenue and earnings than Trevena. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTrevena$443K0.54-$40.29M-$47.04-0.01Bon Natural Life$23.84M0.01$400KN/AN/A Which has more risk & volatility, TRVN or BON? Trevena has a beta of 0.41, indicating that its stock price is 59% less volatile than the S&P 500. Comparatively, Bon Natural Life has a beta of -0.47, indicating that its stock price is 147% less volatile than the S&P 500. Does the media refer more to TRVN or BON? In the previous week, Bon Natural Life had 1 more articles in the media than Trevena. MarketBeat recorded 1 mentions for Bon Natural Life and 0 mentions for Trevena. Trevena's average media sentiment score of 0.00 equaled Bon Natural Life'saverage media sentiment score. Company Overall Sentiment Trevena Neutral Bon Natural Life Neutral SummaryTrevena and Bon Natural Life tied by winning 5 of the 10 factors compared between the two stocks. Get Bon Natural Life News Delivered to You Automatically Sign up to receive the latest news and ratings for BON and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BON vs. The Competition Export to ExcelMetricBon Natural LifeMedicinals & botanicals IndustryDiscretionary SectorNYSE ExchangeMarket Cap$219K$3.44B$8.06B$20.70BDividend YieldN/AN/A3.22%3.67%P/E RatioN/A7.5619.9028.45Price / Sales0.0125.554.7156.07Price / Cash0.785.6216.2523.21Price / Book0.031.134.354.33Net Income$400K$17.44M$218.18M$996.14M7 Day Performance0.77%2.33%3.03%1.98%1 Month Performance-13.82%1.75%-1.75%-0.83%1 Year Performance-97.31%-28.78%20.42%14.36% Bon Natural Life Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BONBon Natural LifeN/A$1.31+2.3%N/A-97.3%$219K$23.84M0.00100TRVNTrevena1.5209 of 5 stars$0.91flat$5.00+449.5%-95.7%$873K$443K-0.0240PBLAPanbela Therapeutics0.0925 of 5 stars$0.16flatN/A-63.3%$767KN/A0.006HEPAHepion Pharmaceuticals0.4693 of 5 stars$0.05-12.2%N/A-99.8%$696KN/A-0.0120Upcoming EarningsGap UpBPTSYBiophytisN/A$1.81flatN/AN/A$634KN/A0.0030VIRXViracta Therapeutics1.6218 of 5 stars$0.01flat$1.75+17,793.7%N/A$389KN/A-0.0120Upcoming EarningsShort Interest ↑NCNANuCana2.399 of 5 stars$0.06-7.7%$25.00+45,354.5%-100.0%$360KN/A-0.0130Upcoming EarningsMYMDMyMD PharmaceuticalsN/A$0.12-11.5%N/A-94.6%$277KN/A0.006Gap DownHigh Trading VolumeSYRSSyros Pharmaceuticals4.0354 of 5 stars$0.01-50.0%$3.33+33,233.3%-100.0%$268K$386K0.00120Gap DownCAPSCapstone TherapeuticsN/A$1.56-2.2%N/AN/A$250K$44.88M0.0038Positive NewsVINCVincerx Pharma2.6721 of 5 stars$0.05+0.4%$40.00+86,480.1%-99.7%$241KN/A0.0060News CoverageUpcoming EarningsGap Up Related Companies and Tools Related Companies Trevena Competitors Panbela Therapeutics Competitors Hepion Pharmaceuticals Competitors Biophytis Competitors Viracta Therapeutics Competitors NuCana Competitors MyMD Pharmaceuticals Competitors Syros Pharmaceuticals Competitors Capstone Therapeutics Competitors Vincerx Pharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:BON) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredFOUR TRILLION DOLLARS!Nvidia just became the first company in history to hit a $4 trillion valuation—surpassing Apple and Microsoft....Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bon Natural Life Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Bon Natural Life With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
